KLH-2109+ Leurprorelin acetate Placebo for leiomyoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Jan 2026: Trial registered, NCT07378098
  2. 3 Feb 2026: Trial started, NCT07378098

The trials

NCT07378098: to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia

State
Under way
Phase
Phase 3
People
254 planned
Started
3 Feb 2026
Primary completion
31 Mar 2028
Arms
KLH-2109+ Leurprorelin acetate Placebo
Results
None posted
  1. 30 Jan 2026: Trial registered
  2. 3 Feb 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.